capsicum oleoresin + ranitidine hydrochloride + diclofenac sodium

A fixed-dose combination product containing **capsicum oleoresin**, **ranitidine hydrochloride**, and **diclofenac sodium**. In practice, this combination has been marketed as package therapies pairing an oral NSAID with an oral H2-receptor antagonist and a topical capsicum preparation, rather than as a single novel molecular entity. Diclofenac sodium is a nonsteroidal anti-inflammatory drug that reduces pain and inflammation primarily by inhibiting cyclooxygenase enzymes and lowering prostaglandin synthesis; ranitidine hydrochloride is a histamine H2-receptor antagonist used to suppress gastric acid secretion and reduce NSAID-associated upper gastrointestinal irritation risk; capsicum oleoresin is a topical counterirritant analgesic whose capsaicinoids activate and subsequently desensitize TRPV1-expressing nociceptive neurons, reducing pain signaling. The combination is intended for symptomatic treatment of musculoskeletal pain and inflammatory conditions while attempting to improve gastrointestinal tolerability of diclofenac.

Other names

capsicum oleoresin + ranitidine hydrochloride + diclofenac sodium